Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post by Robert Orlowski on X, adding:
“Kudos, Moffitt Cancer Center team (Oswald Dorishansen et al) on many fronts:
- PROMIS-29 to measure QOL after SOC, CAR-T in myeloma… free and benchmarked to general population. This is the way!
- Early timepoints, e.g. D7
- Showing CAR-T QOL benefit even in RW pts across products!”
Quoting Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center:
“Myeloma Paper of the Day: Study of patient-reported outcomes after ide-cel vs. cilta-cel CAR-T finds similar PRO trajectories regardless of CAR-T type, with most PROs initially worsening or stable before significantly improving post-treatment.”
You can also read: Myeloma Paper of the Day, May 13th Suggested by Robert Orlowski
Other articles featuring Rahul Banerjee on OncoDaily.